Fennec Pharmaceuticals (FRX) Stock Price, News & Analysis

Company Overview

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Key Stats

• Today's Range: C$11.31 to C$11.38
• 50-Day Range: C$7.02 to C$11.50
• 52-Week Range: C$5.65 to C$11.50
• Volume: 253 shs
• Average Volume: 1,265 shs
• Market Capitalization: C$218.11 million
• P/E Ratio: N/A
• Dividend Yield: 2.02%
• Price Target: N/A
• Consensus Rating: Strong Buy

FRX Stock Analysis - Frequently Asked Questions

How have FRX shares performed this year?

Fennec Pharmaceuticals' stock was trading at C$8.87 at the start of the year. Since then, FRX stock has increased by 27.5% and is now trading at C$11.31.
View the best growth stocks for 2025 here.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc. (TSE:FRX) released its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.10. Fennec Pharmaceuticals had a negative net margin of 2.30% and a positive trailing twelve-month return on equity of 29.94%.

How do I buy shares of Fennec Pharmaceuticals?

Shares of FRX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Fennec Pharmaceuticals investors own include Tilray (TLRY), Aurora Cannabis (ACB), Encanto Potash (EPO), Fennec Pharmaceuticals (FENC), Ocugen (OCGN), Passport Potash (PPI) and Workhorse Group (WKHS).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 5/29/2025

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: TSE:FRX
• CIK: N/A
• Web: fennecpharma.com
• Phone: +1-919-6364530
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 18.73
• P/E Growth: N/A
• Net Income: -C$800.44 thousand
• Net Margins: -2.30%
• Pretax Margin: N/A
• Return on Equity: 29.94%
• Return on Assets: 8.88%

Debt

• Debt-to-Equity Ratio: -620.83
• Current Ratio: 7.80
• Quick Ratio: 10.17

Sales & Book Value

• Annual Sales: C$34.86 million
• Price / Sales: 6.26
• Cash Flow: C$0.97 per share
• Price / Cash Flow: 11.66
• Book Value: C($0.19) per share
• Price / Book: -59.70

Miscellaneous

• Outstanding Shares: 19,284,690
• Free Float: N/A
• Market Cap: C$218.11 million
• Optionable: Not Optionable
• Beta: 0.25